Miskolczi P, Kozma K, Polgár M, Vereczkey L
Department of Pharmacokinetics and Drug Metabolism, Chemical Works of Gedeon Richter Ltd, Budapest, Hungary.
Eur J Drug Metab Pharmacokinet. 1990 Jan-Mar;15(1):1-5. doi: 10.1007/BF03190120.
The pharmacokinetics of vinpocetine (Cavinton) and of its main metabolite apovincaminic acid (AVA), has been studied in 5 healthy male volunteers after the administration of 3 x 5 and 3 x 10 daily doses of vinpocetine for seven days. The pharmacokinetic curves of both vinpocetine and AVA have been determined prior to the chronic administration and on the last day of the treatment, whereas between the 2nd and 6th days, concentration was measured once daily. On the basis of these pharmacokinetic studies it can be concluded that both vinpocetine and AVA show linear pharmacokinetics at the doses used and that there is no accumulation or autoinduction.
已对5名健康男性志愿者进行研究,让他们连续7天每日服用3×5和3×10剂量的长春西汀(卡文通),并对其主要代谢物阿朴长春胺酸(AVA)的药代动力学进行了研究。在长期给药前以及治疗的最后一天测定了长春西汀和AVA的药代动力学曲线,而在第2天至第6天期间,每天测量一次浓度。基于这些药代动力学研究可以得出结论,在所使用的剂量下,长春西汀和AVA均呈现线性药代动力学,且不存在蓄积或自身诱导作用。